Biomarker-Driven Lung Cancer

>

Latest News

FDA Approves Ensartinib in ALK-Positive NSCLC
FDA Approves Ensartinib in ALK-Positive NSCLC

December 18th 2024

The FDA has granted ensartinib approval for adult patients with ALK-positive non–small cell lung cancer.

Sequencing and Management Considerations for ALK TKIs in NSCLC
Sequencing and Management Considerations for ALK TKIs in NSCLC

December 10th 2024

FDA OKs FoundationOne Liquid CDx for Tepotinib in METex14-Skipping NSCLC
FDA OKs FoundationOne Liquid CDx for Tepotinib in METex14-Skipping NSCLC

November 19th 2024

Sunvozertinib New Drug Application in EGFR-Mutant NSCLC Submitted to FDA
Sunvozertinib New Drug Application in EGFR-Mutant NSCLC Submitted to FDA

November 8th 2024

Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC

November 6th 2024

Video Series
Video Interviews

More News